Agios Pharmaceuticals Inc
NASDAQ:AGIO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.32
61.64
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc
Tax Provision
Agios Pharmaceuticals Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Agios Pharmaceuticals Inc
NASDAQ:AGIO
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$63m
|
CAGR 3-Years
68%
|
CAGR 5-Years
48%
|
CAGR 10-Years
30%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$449m
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$739.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-61%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$314.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
3%
|
|
Agios Pharmaceuticals Inc
Glance View
Amid the thriving hub of biotechnology in Cambridge, Massachusetts, Agios Pharmaceuticals Inc. carved a niche for itself with a focused approach on rare and genetically defined diseases. From its inception, Agios set out to revolutionize the treatment landscape by diving into cellular metabolism's intricacies. This was a path less traveled, yet it held the potential to unlock therapies where few solutions previously existed. The company's initial explorations into cancer metabolism pioneered innovative treatments for various malignancies. However, the agility of Agios’s strategic vision was evident when it pivoted to concentrate its resources on the profound potential of precision medicines tailored for unheard-of-conditions like pyruvate kinase deficiency (PKD). To understand how Agios generates revenue, consider its commitment to harnessing deep scientific insights and translating them into impactful therapies. Agios’s revenue model involves the development and commercialization of pioneering therapies that address unmet medical needs, often collaborating with strategic partners to amplify its reach and efficacy in bringing these treatments to market. Moving beyond oncology, the firm now monetizes its research by focusing on a single area of expertise, shifting from developing cancer drugs to innovating within rare genetic disorders. This focused strategy is epitomized by their lead product for PKD, a chronic hemolytic anemia, leading to a revenue model intricately linked to their ability to develop and deliver highly specialized treatments that make a real-world impact on patient lives.
You don't have any saved screeners yet
